Background
==========

After the introduction of highly active antiretroviral therapy (HAART) HIV has changed from a fatal disease to a chronic condition and well treated HIV patients now have an overall life expectancy close to that of non-HIV infected individuals \[[@B1]\]. Due to immunological recovery, there has been a remarkable decline in AIDS defining cancers whereas the increased risk of certain non-AIDS defining cancers, including lung cancer has persisted in the HIV population \[[@B2]-[@B6]\].

Lung cancer is primarily related to tobacco use and the role of HIV infection in the development of lung cancer is uncertain \[[@B7]\]. Several studies have shown that both immunosuppressed patients after allograft organ transplantation and HIV patients are at higher risk of lung cancer \[[@B8]\]. Therefore immunodeficiency and chronic inflammation are proposed to be major risk factors, besides smoking, involved in the lung cancer pathogenesis. Whereas the role of HIV infection in lung cancer development is questionable, most studies show a decreased survival in HIV patients with lung cancer \[[@B9]-[@B12]\]. We hypothesized that family related risk factors may be part of the increased risk of lung cancer and mortality and that HIV is a marker for the increased risk independently of the pathogenicity of HIV. We therefore performed a national cohort study comparing the risk of lung cancer and survival among Danish HIV patients, their parents and a cohort of population controls.

Methods
=======

In the first part of the study we estimate the incidence of lung cancer in 1) HIV patients compared to population controls matched on age and gender and 2) in the parents of the HIV patients compared to the parents of the population controls. In the second part of the study we estimate the mortality of individuals diagnosed with lung cancer in 1) HIV patients compared to population controls matched on age and gender and 2) the parents of the HIV patients compared to the parents of the population controls.

Setting
-------

Denmark had a population of 5.5 million as of 31 December 2008, with an estimated HIV prevalence of approximately 0.09% in the adult population. Patients with HIV infection are treated in the country\'s eight specialized medical centres, where they are seen on an outpatient basis at intended intervals of 12 weeks. As HAART is available only at these eight centres almost no HIV patients are treated elsewhere. Antiretroviral treatment is provided free of charge to all HIV-infected residents of Denmark.

Data sources
------------

We used the unique 10-digit civil registration number assigned to all individuals in Denmark at birth or upon immigration to link the data sources described below \[[@B13]\].

The Danish HIV Cohort study (DHCS) is a population-based prospective nationwide cohort study of all HIV patients 16 years or older at diagnosis and who are treated at Danish HIV centres after 1 January 1995 \[[@B14]\]. The HIV patients are consecutively enrolled, and multiple registrations are avoided through the use of the unique civil registration number. December 31, 2009 the cohort included 5481 Danish residents. Data are updated yearly and includes demographics, smoking status, date of HIV infection, AIDS defining events, date and cause of death and antiretroviral treatment. CD4^+^cell counts and HIV-RNA measurements are extracted electronically from laboratory data files. Data on smoking are not adequate in the database. Patients who were registered at least once as consuming tobacco in any quantity were considered smokers or former smokers. We calculated the distribution of smokers or former smokers among Danish HIV infected.

The Danish Civil Registration System (DCRS) was established in 1968 and stores information of vital status, residency as well as immigration and emigration on all Danish residents \[[@B13]\]. Since 1 January 1969 the registry also included identification of parents still alive at this date.

The Danish Cancer Register is a population-based register and contains information on incident cancers diagnosed in Danish Citizens since 1943. Details about registration can be found elsewhere \[[@B15]\]. In 1969 - 2003 cancers were coded according to International Classification of Disease version 7 (ICD-7) and International Classification of Diseases for Oncology 1 (ICD-O-1) with supplement from ICD-O-2 in 1990 - 2003. Since 2004 cancers have been coded according to ICD-O-3 and ICD-10 and data from the period 1978 - 2003 have been converted to ICD-O-3 and ICD-10. We do not have data on cancer staging or treatment from the Danish Cancer Register.

Data on smoking are not available in the Danish national registries.

Study populations
-----------------

### HIV and population control Study populations

In the first part of the study, we included all HIV patients from the Danish HIV Cohort Study without a diagnosis of cancer prior to index date, see Figure [1](#F1){ref-type="fig"}. The index date was defined as 1 January 1995, the date of the HIV diagnosis or date of immigration, which ever came last. For each of the HIV patients we identified 10 age- and gender matched population control subjects from the DCRS who were alive and living in Denmark at index date of the corresponding HIV patient (refereed to also as the index date of the respective population control) and not diagnosed with a cancer prior to index date.
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### Parent study populations

In the parent study population we included all mothers and fathers of the HIV patients and population controls included who 1) gave birth to a index patient or population control after 1 January 1952, 2) were alive and living in Denmark after 1 January 1969 and 3) who were not diagnosed with cancer prior to the parent index date, see Figure [1](#F1){ref-type="fig"}. The parent index date was defined as 1 January 1969, date of birth of the included HIV patient/population control or date of registration in DCRS, whichever came last. In case a parent was the father or mother of both an HIV patient and a population control, they were included in both parent populations.

Outcome
-------

In the first study outcome was time to first diagnosis of lung cancer. We identified all primary lung cancers in the populations using cancer diagnoses as defined by NORDCAN \[[@B16]\]; see cancer definitions in Additional file [1](#S1){ref-type="supplementary-material"}. Lung cancer was defined according to NORDCAN: 1620, 1621, 1628 in ICD-7 and C34 in ICD-10. In order to investigate if there was any difference in the histopathological distribution of lung cancer perhaps due to immunodeficiency we grouped the lung cancers into five groups following the 1999 WHO classification \[[@B17]\] categorized by the following ICD-O-3 codes; 1) squamous cell carcinoma (M80503 - 80763, M80833), 2) small cell carcinoma (M80403 - 80453), 3) adenocarcinoma (M82303 -823133, M82503 - 82603, M84803 - 84903, M85503 - 85603, M85703 - 85723, M81403, M82113, M83233) 4) large cell carcinoma (M80123 -80313, M83103) and 5) other carcinomas (M85603, M82403, M82493, M84303, M82003, M85623, M80463) and unclassified malignant cells (M80013, M80103, M82463, M99903, M99993).

In the second part of the study outcome was time to death.

Statistics
----------

Differences in characteristics between groups were evaluated by the χ^2^test and Kruskal-Wallis Test when appropriate.

We estimated the probability of lung cancer and the relative risk of lung cancer in all study populations. Observation time was calculated from the respective index date to date of diagnosis of lung cancer or other cancers, death, 1 January 2009, emigration or lost to follow-up, whichever came first. We used cumulative incidence function to illustrate time to first lung cancer, recognizing death and diagnoses of other cancers as a competing risk \[[@B18]\]. Incidence rate ratios (IRR) and 95% confidence intervals for lung cancer as estimates of relative risks were calculated using Cox proportional-hazards regression. In the comparison of HIV patients and their matched population controls we used Cox regression analyses stratified according to the initial match criteria (age and gender).

In order to identify risk factors for lung cancer in the HIV population, we calculated incidence rate ratios (IRRs) stratified by gender, race (native vs. immigrant), age at index date (≤ 50 years vs. \> 50 years), diagnosis of HIV before 1 January 1995, smoking (smoker or former smoker in any quantity vs. never smoked), route of infection (men who have sex with men (MSM) vs. heterosexually infected men vs. heterosexually infected women vs. injection drug user (IDU)), immunodeficiency at index date (AIDS defining event or CD4 cell count \< 350 cells/μL vs. no AIDS defining event and CD4 cell count ≥ 350 cells/μL). All results were adjusted for age (continuous variable) and gender. Baseline CD4 cell count was defined as the measurement closest to index date +/- one year. Also, we included first date with a CD4 count below 350/μL or date of first AIDS defining event as a time dependent variable.

IRRs for parent populations were adjusted for age at parent index date (continuous variable) as well as year of birth of the parent divided into the following decades: - 1920, 1920-1930, 1930-1940, 1940-1950, 1950 - later. A robustness analysis was performed where we calculated IRRs for lung cancer including only parents of HIV patients and population controls born in Denmark.

In a sub analysis, we calculated IRR for the following four types of lung cancers: Squamous cell carcinoma, small cell carcinoma, adenocarcinoma and large cell carcinoma.

We computed person-years at risk of dying from lung cancer from date of the diagnosis to date of death, 1 January 2009, emigration or lost to follow up whichever came first. We used Kaplan-Meier analysis to construct survival curves and Cox regression analyses were used to estimate mortality rate ratios (MRR). In the population consisting of HIV patients and population controls all results were adjusted for age at lung cancer diagnosis (continuous variable) and gender. In the parent population all results were adjusted for age at lung cancer diagnosis (continuous variable) as well as year of birth of the parent divided into the following decades: - 1920, 1920-1930, 1930-1940, 1940-1950, 1950 - later. The study was approved by the Danish Data Protection Agency. SPSS statistical software, Version 15.0 (Norusis; SPSS Inc., Chicago, Illinois, USA) and R software, version 2.8.1, was used for data analysis.

Results
=======

In the first part of the study, we identified a total of 5,168 Danish HIV patients of which 115 were excluded due to cancer diagnosed prior to index date, leaving 5,053 HIV patients and 50,530 age and gender matched population controls in the study with a total of 37,622 and 470,322 person-years of follow-up, respectively (figure [1](#F1){ref-type="fig"}). 1,165 (23.1%) died during follow-up, 17 (0.3%) were lost to follow-up and 173 (3.4%) emigrated. 85.8% of the HIV patients were male, 71.6% were native Danes and 45.3% were MSMs. More patient characteristics are described in table [1](#T1){ref-type="table"}. 71.1% of the HIV study population were smokers or former smokers in any quantity and females and immigrant were less likely to smoke whereas almost all IDUs smoked or used to smoke (Additional file [2](#S2){ref-type="supplementary-material"}).

###### 

Characteristics of HIV patients and population controls with lung cancer

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                  HIV patients\        HIV patients with lung cancer\       Population controls with lung cancer\       P value\*
                                                                                                                  N = 5053,            N = 29,                              N = 183,                                    
  --------------------------------------------------------------------------------------------------------------- -------------------- ------------------------------------ ------------------------------------------- -------------
  Male gender                                                                                                     3827 (75.7)          27 (93.1)                            156 (85.2)                                  0.253

  Age at time of index date, median (IQR), years                                                                  36.6 (30.4 - 44.3)   49.9 (42.7 - 59.7)                   50.7 (45.1 - 59.5)                          0.554

  Age at time of cancer diagnosis, median (IQR), years                                                            \-                   57.0 (48.8 - 63.2)                   58.9 (52.2 - 67.5)                          0.192

  Native Danes                                                                                                    3619 (71.6)          24 (82.8)                            179 (97.8)                                  \> 0.001

  Older than 50 years at index date                                                                               695 (13.8)           14 (58.3)                            98 (53.6)                                   0.129

  Diagnosed with HIV before 1 January 1995                                                                        1968 (38.9)          18 (62.1)                                                                        

  Smoker or former smoker in any quantity                                                                         2600 (71.1)          29 (100)                                                                         

  Route of HIV infection                                                                                                                                                                                                

   Men who have sex with men                                                                                      2287 (45.3)          12 (41.4)                                                                        

   Heterosexually infected men                                                                                    934 (18.5)           12 (41.4)                                                                        

   Heterosexually infected women                                                                                  930 (18.4)           2 (6.9)                                                                          

   Injection drug user                                                                                            553 (10.9)           3 (10.3)                                                                         

   Other                                                                                                          349 (6.9)            0 (0.0)                                                                          

  Baseline CD4 \< 350 cells/μL or AIDS defining event at index date                                               2655 (52.5)          20 (69.0)                                                                        

  Baseline CD4 cell count, cells/μL, median (IQR)                                                                 279 (104 - 480)      230 (86 - 403)                                                                   

                                                                                                                                                                                                                        

  **Histological classification of lung cancer**                                                                                       **HIV patients with lung cancer**\   **Population controls with lung cancer**\   **P value**
                                                                                                                                       **N = 29**                           **N = 183**                                 

                                                                                                                                                                                                                        

   Squamous cell carcinoma                                                                                                             8 (27.6)                             36 (19.7)                                   

   Small cell carcinoma                                                                                                                4 (13.8)                             31 (16.9)                                   

   Adenocarcinoma                                                                                                                      7 (24.1)                             55 (30.1)                                   

   Large cell carcinoma                                                                                                                0 (0)                                12 (6.5)                                    

   Other and unclassified                                                                                                              10 (34.5)\*\*                        49 (26.8)\*\*\*                             

  **P value for difference in distribution of HPV site, potential HPV site and potentially unrelated HPV site**                                                                                                         0.457
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*P value for differences in characteristics between HIV patients and population controls with lung cancer

\*\*3 carcinoma without other specifications (M80103), 3 Non-Large cell carcinomas (M80463), 2 adenosquamos carcinomas (M85603), 1 no microscopically confirmed lung cancer (M99903) and 1 malignant histology unknown (M99993).

\*\*\*2 neoplasm malignant (M80003), 3 malignant tumor cells (M80013), 3 carcinoma without other specifications (M80103), 22 Non-Large cell carcinomas (M80463), 3 carcinoid tumor, malignant (M82403), 1 neuroendocrine carcinoma (M82463), 1 adenosquamous carcinomas (M85603), 12 not microscopically confirmed lung cancer (M99903) and 2 malignant histology unknown (M99993).

A total of 333 (6.6%) HIV patients and 1328 (2.6%) population controls were diagnosed with a cancer in the observation period of whom 29 (0.6%) and 183 (0.4%), respectively, were diagnosed with lung cancer. Median age at time of lung cancer was not significantly different in the two cohorts. Their characteristics are listed in table [1](#T1){ref-type="table"}. All HIV patients with lung cancer were smokers. 20 (69.0%) of the HIV patients were treated with HAART before diagnosed with lung cancer. Nadir CD4 cell count in the HIV patients diagnosed with lung cancer was 110 cells/μL (IQR; 45 cells/μL - 230 cells/μL) and median CD4 cell count at time of cancer diagnosis was 299 cells/μL (IQR; 130 cells/μL - 521 cells/μL). 17 (85.0%) of those in HAART were virally suppressed at time of lung cancer diagnose.

As seen in figure [2](#F2){ref-type="fig"}, the HIV infected population had a higher 10-year probability for lung cancer compared to the control population. The incidence of lung cancer was higher in HIV patients than in population controls (adjusted IRR 2.38 (95% CI; 1.61 - 3.53)). The IRRs for lung cancer remained high in most stratified analyses except for female HIV patients. No events of lung cancer were diagnosed among HIV patients who never smoked (table [2](#T2){ref-type="table"}). The highest risk of lung cancer were seen in HIV patients who were smokers or former smokers (adjusted IRR; 4.06 (95% CI; 2.66 - 6.21), male patients with heterosexual route of HIV infection (adjusted IRR; 4.19 (95% CI; 2.20 - 7.96)) and HIV patients with prior AIDS defining events or low baseline CD4 cell count (adjusted IRR; 3.25 (95% CI; 2.01 - 5.24)).
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###### 

Risk factors for lung cancer for HIV patients and population controls

                                                                          Lung cancer (HIV/population controls), N   Unadjusted IRR (95% CI)   Adjusted IRR\* (95% CI)
  ----------------------------------------------------------------------- ------------------------------------------ ------------------------- -------------------------
  All                                                                     29/183                                     2.08 (1.41 - 3.08)        2.38 (1.61 - 3.53)
                                                                                                                                               
  **Stratification**                                                                                                                           
                                                                                                                                               
  Male gender\*                                                           27/156                                     2.33 (1.55 - 3.50)        2.66 (1.77 - 4.01)
  Female gender                                                           2/27                                       0.91 (0.22 - 3.82)        \*\*
  Native                                                                  24/179                                     2.13 (2.39 - 3.27)        2.56 (1.47 - 3.46)
  Immigrant                                                               5/4                                        6.38 (1.71 - 23.86)       \*\*
  Younger than or 50 years at index date                                  18/104                                     2.33 (1.35 - 4.04)        2.34 (1.35 - 4.06)
  Older than 50 years at index date \*                                    14/98                                      2.07 (1.18 - 3.63)        2.08 (1.19 - 3.65)
  HIV diagnosed before 1995                                               18/112                                     2.34 (1.42 - 3.85)        2.60 (1.58 - 4.28)
  HIV diagnosed after 1995 at index date                                  11/71                                      1.75 (0.93 - 3.31)        2.13 (1.12 - 4.03)
  Smoker or former smoker in any quantity                                 29/81                                      3.79 (2.48 - 5.97)        4.06 (2.66 - 6.21)
  Never smoked                                                            0/35                                       \*\*                      \*\*
  Route of HIV infection                                                                                                                       
   Men who have sex with men (MSM)                                        12/99                                      1.60 (0.88 - 2.91)        1.82 (0.99 - 3.12)
   Heterosexually infected men                                            12/44                                      3.40 (1.80 - 6.45)        4.19 (2.20 - 7.96)
   Heterosexually infected women                                          2/18                                       1.26 (0.30 - 5.44)        \*\*
   Injection drug user (IDU)                                              3/13                                       1.95 (1.28 - 2.94)        \*\*
  Baseline CD4 \< 350 cells/μL or AIDS defining event at index date       20/111                                     2.70 (1.68 - 4.35)        3.25 (2.01 - 5.24)
  Baseline CD4 *≥*350 cells/μL and no AIDS defining event at index date   6/40                                       1.68 (0.71 - 3.96)        1.71 (0.72 - 4.03)

\* All adjusted for gender and age, except the stratification on male which is only adjusted for age and age \> 50 which is only adjusted for gender.

\*\* Too few events for analysis.

In the time period after first date with a CD4 cell count below 350 cells/μL or an AIDS defining event the adjusted RR for lung cancer was 1.48 (95% CI; 0.63 - 3.47)) compared to HIV patients with intact or restituted immune system.

We identified a total of 2,428 fathers of HIV infected individuals vs. 31,929 fathers of population controls and 2,586 mothers of HIV patients and 32,705 mothers of population controls (figure [1](#F1){ref-type="fig"}). Age at paternal index date and median follow-up time did not differ between the parent populations (table [3](#T3){ref-type="table"}). The 30-year probability of lung cancer was higher for both fathers and mothers of HIV patients (figure [3](#F3){ref-type="fig"}). The adjusted relative risk for lung cancer for fathers and mothers of HIV patients was 1.31 (95% CI: 1.09 - 1.58) and 1.35 (95% CI: 1.07 - 1.70), respectively. After stratification of the children\'s route of HIV infection, the relative risk remained high in all groups particularly for parents of IDUs (adjusted IRR for HIV fathers; 1.63 (95% CI: 1.02 - 2.58), adjusted IRR for HIV mothers; 2.01 (95% CI: 1.21 - 3.36)) (table [4](#T4){ref-type="table"}).

###### 

Characteristics of parents of HIV patients and population controls

                                                            Fathers of HIV patients   Fathers of population controls   Mothers of HIV patients   Mothers of population controls
  --------------------------------------------------------- ------------------------- -------------------------------- ------------------------- --------------------------------
  All                                                       2,428                     31,929                           2,586                     32,705
  Median age at index date, years (IQR).                    34.3 (28.6 - 41.9)        33.4 (28.3 - 40.6)               30.9 (25.8 - 37.5)        30.5 (25.7 - 36.7)
  Follow-up time, median, years (IQR)                       34.5 (25.2 - 40.0)        35.5 (27.6 - 40.0)               37.5 (29.0- 40.0)         38.4 (31.3 - 40.0)
  Duration of follow-up, years                              75,125                    1,026,778                        86,024                    1,124,126
  Emigration during follow-up, N (%)                        41 (1.7)                  327 (1.0)                        31 (1.2)                  219 (0.7)
  Lost to follow-up, N (%)                                  4 (0.1)                   13 (\<0.1)                       2 (0.1)                   2 (\<0.1)
  Diagnosed with all lung cancers, (N (%))                  122 (5.0)                 1233 (3.9)                       78 (3.0)                  763 (2.3)
  Median age at diagnose of all lung cancers, years (IQR)   65.7 (60.1 - 72.8)        65.6 (59.3 - 71.5)               60.4 (55.2 - 68.9)        64.1 (58.2 - 69.9)
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###### 

Incidence rate ratios for lung cancer for the parent population stratified for the offspring\'s route of HIV infection

                                             Cancer, N   Unadjusted IRR (95% CI)   Adjusted IRR\* (95% CI)
  ------------------------------------------ ----------- ------------------------- -------------------------
  **All fathers of HIV patients\*\***        122/1233    1.38 (1.14 - 1.66)        1.31 (1.09 - 1.58)
                                                                                   
  **Stratification**                                                               
                                                                                   
  **Route of HIV infection for offspring**                                         
   Men who have sex with men (MSM)           65/535      1.34 (1.04 - 1.73)        1.24 (0.96 - 1.61)
   Heterosexually infected                   31/440      1.39 (0.97 - 2.00)        1.31 (0.91 - 1.89)
   Injection drug user (IDU)                 20/183      1.40 (0.89 - 2.23)        1.63 (1.02 - 2.58)
                                                                                   
  **All mothers of HIV infected\*\*\***      78/763      1.37 (1.08 - 1.72)        1.35 (1.07 - 1.70)
                                                                                   
  **Stratification**                                                               
                                                                                   
  **Route of HIV infection for offspring**                                         
   Men who have sex with men (MSM)           41/342      1.29 (0.93 - 1.78)        1.26 (0.90 - 1.73)
   Heterosexually infected                   17/262      1.20 (0.73 - 1.96)        1.20 (0.73 - 1.96)
   Injection drug user (IDU)                 17/112      1.84 (1.10 - 3.06)        2.01 (1.21 - 3.36)

\* Adjusted for age at parent index date (continuous variable) as well as year of birth of the parent divided into the following decades: - 1920, 1920-1930, 1930-1940, 1940-1950, 1950 - later.

\*\* There were five cases of lung cancer among fathers of children who had other route of HIV infection and 85 among fathers of population controls.

\*\*\* There were one case of lung cancer among mothers of children who had other route of HIV infection

Sub-analyses
------------

In a sub analysis including only squamous cell carcinoma, small cell carcinoma, adenocarcinoma and large cell carcinoma, 19 (0.4%) and 134 (0.3%) lung cancers where diagnosed in the HIV patients and population controls, respectively. The adjusted IRR was 2.11 (95% CI: 1.30 - 3.42). In the parent population, 85 (3.4%) vs. 965 (2.9%) lung cancers were diagnosed in the fathers and 60 (2.2%) vs. 597 (1.8%) in the mothers. The IRRs were increased in both parents of HIV patients (HIV fathers adjusted; 1.17 (95% CI: 0.93 -1.76), HIV mothers adjusted; 1.32 (95% CI: 1.01 -1.72)). Also in a robustness analysis including only parents of HIV patients and population controls born in Denmark, the relative risks of lung cancer were increased (HIV fathers adjusted; 1.39 (95% CI: 1.15 -1.68), HIV mothers adjusted; 1.35 (95% CI: 1.06 -1.72)).

Mortality
---------

25 HIV patients and 149 population controls with lung cancer died during follow-up. Median survival time for the HIV infected population was approximately two months and seven months for the population controls (figure [4](#F4){ref-type="fig"}). Adjusted MRR for the HIV patients with lung cancer was 2.33 (95%CI; 1.51 - 3.51).
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Survival in the parent populations did not differ between parents of HIV patients and population controls (HIV fathers adjusted MRR; 0.97 (95%CI; 0.80 - 1.18), HIV mothers adjusted; 0.96 (95%CI; 0.75 - 1.23).

Discussion and Conclusion
=========================

We found a more than twofold increased risk of lung cancer in HIV patients compared with the background population. The risk was especially increased in HIV patients who were smokers or former smokers, heterosexually infected men or immunosuppressed. Both fathers and mothers of HIV patients had an increased risk of lung cancer compared to the parents of the non-HIV infected population controls. All HIV patients diagnosed with lung cancer were smokers or former smokers and HIV appeared to be a marker of behavioural or family related risk factors that affect the incidence of lung cancer independently of immunosuppression. Also the risk of death was more than twofold increased in the HIV infected population with lung cancer compared to the background population. The increased risk of death in patients with lung cancer appears to be related to the HIV infection since parents of HIV infected with lung cancer did not have an increased mortality.

To our knowledge this is the first nationwide study comparing the incidence of lung cancer in HIV patients with that of a matched control population. A major strength of the study is the quality and coverage of the Danish registries with access to valid data on family members and the population-based design with long and nearly complete follow-up.

We did not estimate the risk of lung cancer and death according to the implementation of HAART. However, the development of lung cancer presumably takes several years and it is therefore difficult to estimate the impact of risk factors that vary over time. Our registry data did not allow direct adjustment for potential effects of confounders like smoking. Therefore we chose to include the parent population in order to demonstrate a family related risk associated with lung cancer as an indirect measure of risk behaviour. Our cohort had a size that allowed us to detect the risk of rare outcomes such as lung cancer. The small number of cases caused some imprecision of our estimates and did not allow us to perform complex multivariate analyses. Our study is based on data extracted from registries and misclassification cannot be ruled out. Still, calculations performed on specific histologically confirmed lung cancer diagnoses confirmed the increased risk in HIV patients. We were not able to include data on lung cancer staging in the mortality analysis which could confound our results. Finally, a limitation of the study is the difference in the proportion of traceable parents among HIV patients and population controls due to a larger proportion of immigrants among the HIV patients. However, a robustness analysis including only parents of HIV patients and population controls born in Denmark confirmed the increased risk of lung cancer among parents of HIV patients.

We observed a twofold increased risk of lung cancer in the HIV infected population which corresponds to the findings of other studies that estimated standardized incidence ratios on population based material \[[@B5],[@B19],[@B20]\]. All lung cancers are related to smoking, especially squamous cell carcinoma and small cell carcinoma \[[@B21]\]. We found a high prevalence of smoking among the Danish HIV patients, where little less than 30% never smoked compared to 40% among adults in the general background population in Denmark in the period 1987 - 2005 \[[@B22]\]. Accordingly, HIV patients who were smokers or former smokers had a considerably increased risk of lung cancer whereas no cases of lung cancer occurred among non-smoking HIV patients. The risk of lung cancer was low for women with HIV but considerably increased for HIV infected males with heterosexual route of infection, HIV patients with previous AIDS defining events or low CD4 cell count in both the stratified and time-update analysis. In the general population the risk of lung cancer is lower in females corresponding to our finding but the estimate was based on few events \[[@B23]\]. The relative risk was considerably increased in male patients with heterosexual route of infection although the prevalence of smoking did not differ compared to homosexually infected individuals. Guiguet et al found an inverse correlation between risk of lung cancer and decreasing CD4 cell count \[[@B24]\]. In accordance with this and other studies we found that immunosuppression predicts risk of lung cancer \[[@B8]\]. The mechanism behind this is unknown but although patients with immunodeficiency at time of inclusion did not smoke more than the rest of the HIV infected population, immunodeficiency may accentuate the oncogenic effects of smoking. Corresponding to the findings of other studies we found no difference in the distribution of histopathological sub-types of lung cancer in the two populations pointing towards a common set of risk factors (probably smoking) \[[@B10],[@B11]\].

Also parents of HIV patients in general and in particular parents of IDUs have an excess risk of lung cancer implying that family associated or behavioral risk factors are involved. Smoking is related to risk-taking behaviour which is moderately to strongly related to heritability and offspring of smokers have a four times higher risk of initiating smoking \[[@B25],[@B26]\]. Several studies has been conducted on this subject and concerning smoking a social learning model of smoking initiation has been demonstrated where adolescents imitate the behaviour of adults over time with repeated exposure \[[@B27]\]. Knowing that the prevalence of smoking is high in the Danish HIV patients it seems likely that smoking explains a substantial part of the increased risk of lung cancer in both the HIV patients and parents. HIV therefore appears to be a marker of family related risk factors that affect the incidence of lung cancer.

In concordance with other studies HIV patients diagnosed with lung cancer had an increased mortality compared to the population controls \[[@B10]-[@B12]\]. This result may be confounded by an increased competing risk of death in the HIV infected population or differences in staging of lung cancer, which we were not able to adjust for. No difference in mortality was seen in the parent population suggesting that the decreased survival in HIV patients is related to HIV and not family related risk factors.

In conclusion, the risk was especially increased in HIV patients who were smokers or former smokers, heterosexually infected men or immunosuppressed. The higher risk of lung cancer in both HIV patients and their parents suggest that family associated risk factors, like tobacco use, explain part of the increased risk in HIV patients. HIV appears to be a marker of behavioural or family related risk factors that affect the risk of lung cancer. The use of tobacco is the major risk factor for lung cancer and future interventions should focus on cessation and preventing initiation of smoking.
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